Bio-Techne Reports Q2 Earnings, Sees Strength in Large Pharma Offset by Biotech and Academia Softness

Got story updates? Submit your updates here. ›

Bio-Techne reported second-quarter fiscal 2026 results that management said were largely in line with internal expectations, as strength from large pharmaceutical customers was offset by softness in emerging biotech and U.S. academia, along with temporary order timing headwinds tied to two large cell therapy customers. The company saw organic revenue growth of 0% in the quarter, with adjusted EPS up 10% year-over-year.

Why it matters

Bio-Techne's results highlight the ongoing split between large pharmaceutical companies and emerging biotech firms, with the former continuing to drive growth while the latter face softness. The company's exposure to the academic and cell therapy markets also makes it vulnerable to order timing dynamics, which impacted its Q2 performance. Understanding these dynamics is crucial for investors to assess Bio-Techne's long-term growth trajectory.

The details

Bio-Techne reported total revenue of $295.9 million, flat year-over-year on both a reported and organic basis. Strength from large pharmaceutical customers was offset by softness in emerging biotech and U.S. academia, along with temporary order timing headwinds tied to two large cell therapy customers. Adjusted EPS was $0.46, up 10% year-over-year, including a favorable $0.04 impact from foreign exchange. GAAP EPS was $0.24, compared with $0.22 a year earlier. Profitability improved despite gross margin pressure, with adjusted operating margin expanding about 100 basis points year-over-year to 31.1%.

• Bio-Techne reported second-quarter fiscal 2026 results on February 7, 2026.

What they’re saying